56% of rural U.S. counties have zero buprenorphine prescribers, leaving rural opioid patients without access to first-line medication

56% of rural counties in the United States lack a single provider who can prescribe buprenorphine, the FDA-approved first-line medication for opioid use disorder, compared to only 2% of urban areas. 74% of rural counties have low-to-no buprenorphine treatment capacity overall. Why it matters: rural patients with opioid use disorder cannot access evidence-based medication, so they must travel hours to urban clinics or go untreated, so untreated patients continue using illicit opioids contaminated with fentanyl and xylazine, so overdose death rates in rural counties continue climbing disproportionately, so entire rural communities lose working-age adults and deepen cycles of poverty, disability, and family dissolution. The structural root cause is that buprenorphine prescribing was historically gated behind a federal X-waiver system (removed in January 2023 by the Consolidated Appropriations Act), but the damage was done: few rural primary care physicians developed the clinical confidence, institutional support, or patient pipelines to treat opioid use disorder, and pharmacy-level barriers (insufficient stock, pharmacist moral objections, and stigma-driven refusal to fill prescriptions) persist even where prescribers now exist.